Mehmet Kirnap

Mehmet Kirnap

Auto-generated profile, based on publicly available information

Mehmet Kirnap

Department of Physical Medicine and Rehabilitation, Faculty of Medicine, Erciyes University, Kayseri, Türkiye

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 October 2022 in Northwestern Medical Journal
Verified
Journal Article
Open access
ŞKŞerife Mehlika Kuşkonmaz
Şerife Mehlika Kuşkonmaz
GKGönül Varan Koç
Gönül Varan Koç
TÖTahsin Özenmiş
Tahsin Özenmiş
MImuhammed mustafa Ince
muhammed mustafa Ince
MKMehmet Kırnap
Mehmet Kırnap
CÇCavit Çulha
Cavit Çulha


15 March 2026 in Bozok Tıp Dergisi
Verified
Journal Article
Closed access
SBSinem Kübra Beke
Sinem Kübra Beke
HKHÜSEYİN KAPLAN
HÜSEYİN KAPLAN
EUElçin Ulusoy
Elçin Ulusoy
IYİrEm Yavuz
İrEm Yavuz
GCGizem Cengiz
Gizem Cengiz
MÇMustafa Çalış
Mustafa Çalış
Purpose: This study aims to investigate the use of gabapentinoids (gabapentin and pregabalin) in the management of pain in musculoskeletal diseases, and to evaluate the demographic characteristics, comorbidities and reasons for prescribing these drugs.Materials and Methods: Between January 2023 and July 2024, 615 patients aged ≥18 years who applied to Erciyes University Faculty of Medicine- Physical Medicine and Rehabilitation and Rheumatology outpatient clinic and received gabapentinoid treatment were retrospectively analyzed. Demographic characteristics, comorbidities, laboratory values [C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), blood urea nitrogen (BUN), estimated glomerular filtration rate (eGFR), and creatinine], doses of gabapentinoid drugs, and reasons for prescription were obtained from the patient record system.Results: The mean age of the patients included in the study was 59.8±12.6 years and 78.2% were female. The most common comorbidities in all patients were hypertension (51.3%), rheumatological diseases (36.5%) and diabetes mellitus (30.3%), respectively. The most common rheumatological diseases were rheumatoid arthritis (40.6%) and spondyloarthritis (39.3%). The rate of rheumatological comorbidity was statistically significantly higher in the pregabalin group (60.5%) compared to the gabapentin group (32.8%) (p

7 August 2025 in Scientific Reports
Verified
Journal Article
Open access
PDF file
HKHÜSEYİN KAPLAN
HÜSEYİN KAPLAN
GCGizem Cengiz
Gizem Cengiz
HKHasan Kara
Hasan Kara
İCİsa Cüce
İsa Cüce
MKMehmet Kirnap
Mehmet Kirnap
MÇMustafa Çaliş
Mustafa Çaliş
We aimed to determine the use/prescription rates of biosimilars (BSs) among patients being treated with biologic or targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs). This retrospective study included 647 patients with axial spondyloarthritis (axSpA) and rheumatoid arthritis (RA). Patients’ manual and electronic file records were reviewed and demographic, clinical, laboratory, and treatment-related data were collected. Details of the last prescribed and previously used b/tsDMARDs were noted. The data obtained were compared between groups according to disease type or BSs use. Logistic regression analysis was used to identify potential predictors associated with prescribing BSs. The mean age of all the patients was 48.1 ± 12.6 years, and 66% of the patients were women. The rate of BS use was 21.2% in all patients, and there was no significant difference in the rate of BS use between the axSpA and RA groups (22.2% vs. 19%; p = 0.337). The total duration of all b/tsDMARDs use was 4.3 (1–8.3) years in all patients. Although there was no difference between the patients with axSpA and RA in terms of total treatment duration with the last b/tsDMARD (p = 0.655), the total duration of all b/tsDMARDs use was significantly higher in patients with RA than in patients with axSpA (p = 0.001). The use of BSs increased with the number of treatment switches and prescription order(s) of b/tsDMARDs. The BSs prescription rate (39.7%) was highest in drugs prescribed as fifth order or later in patients with prior use of five or more distinct b/tsDMARDs. Female sex, disease duration, and the order of current b/tsDMARD were the most important predictors of preference for BSs over reference drugs. Approximately one in five patients were prescribed BSs among the patients being treated with b/tsDMARDs. The use/prescription rates of BSs were independent of disease type. In patients receiving two or more different b/tsDMARDs, the prescription rates for BSs tended to rise with later treatment line(s) relative to first-line b/tsDMARDs.